CCR4 and neoplasm: The frequency of tumor-infiltrating aTreg cells was also lower in the CCR4 antagonist-treated group than in the PBS/blank control groups (P < 0.05 for each), suggesting that the CCR4 antagonist inhibited aTreg cell migration in vivo (Figure 6C).